Tvardi Therapeutics, Inc. Securities Fraud Investigation

Shamis & Gentile, P.A. is investigating claims on behalf of investors of Tvardi Therapeutics, Inc. ("Tvardi Therapeutics" or the "Company") (TVRD). Impacted investors are advised to contact the firm now.

The law firm is investigating whether Tvardi Therapeutics misrepresented or omitted material information regarding the development and prospects of its lead drug candidate, TTI-101. Between late May 2025 and early October 2025, Tvardi Therapeutics issued multiple public statements describing TTI-101’s “unique and powerful dual mechanism” and expressing confidence in the ongoing REVERT IPF Phase 2 clinical trial for idiopathic pulmonary fibrosis (IPF).

On October 13, 2025, Tvardi Therapeutics announced that its REVERT IPF Phase 2 trial did not meet its primary endpoints. The Company reported that TTI-101 showed no observed benefit over placebo and that higher dropout rates occurred among treated participants.

Following this news, Tvardi Therapeutics' stock price fell approximately $34.91 per share, or about 84%, declining from $41.60 on October 10, 2025 to close at $6.69 on October 13, 2025, causing substantial loss in market capitalization.

If you purchased Tvardi Therapeutics (NASDAQ: TVRD) between late May 2025 and early October 2025, you may be eligible to seek compensation for your losses. Contact Shamis & Gentile today to discuss your options.

Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.

Attorney advertising. Prior results do not guarantee similar outcomes.